
Clinical TrialNov 20, 2026, 04:12 PM
PMV Pharma: Rezatapopt Shows 48% ORR in Ovarian Cancer Phase 2 Trial
AI Summary
PMV Pharmaceuticals, Inc. announced updated data from the Phase 2 pivotal portion of the PYNNACLE clinical trial for rezatapopt, a therapy targeting TP53 Y220C-mutated advanced solid tumors. The trial showed a 48% confirmed overall response rate (ORR) with a 10.4-month median duration of response in the primary analysis population of 65 platinum-resistant/refractory ovarian cancer patients. Across all cohorts in the overall population of 168 evaluable patients, the ORR was 36% with an 8.1-month median duration of response. The company plans to submit a New Drug Application (NDA) for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
Key Highlights
- PMV Pharma announced updated Phase 2 data for rezatapopt in TP53 Y220C-mutated advanced solid tumors.
- 48% confirmed overall response rate (ORR) in 65 platinum-resistant/refractory ovarian cancer patients.
- 10.4-month median duration of response in the primary ovarian cancer population.
- 36% ORR across all cohorts in the overall population of 168 evaluable patients.
- 8.1-month median duration of response in the overall population.
- NDA submission for platinum-resistant/refractory ovarian cancer planned for Q1 2027.
- Data presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026).
Price Impact
More from PMVP